{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:41:45Z","timestamp":1769186505373,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clml.2021.07.029","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T17:18:23Z","timestamp":1627838303000},"page":"775-784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"21","author":[{"given":"Cristina","family":"Gasparetto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian M.","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lura","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Mander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlando F.","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Arriola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.029_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.029_bib0002","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2021.07.029_bib0003","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bmt.2015.307","article-title":"Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity","volume":"51","author":"Cornell","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.07.029_bib0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.029_bib0005","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.07.029_bib0006","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.07.029_bib0007","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.07.029_bib0008","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2021.07.029_bib0009","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","article-title":"Bcl-2-family proteins and hematologic malignancies: history and future prospects","volume":"111","author":"Reed","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.029_bib0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fonc.2018.00533","article-title":"Role and regulation of pro-survival BCL-2 proteins in multiple myeloma","volume":"8","author":"Slomp","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2021.07.029_bib0011","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2021.07.029_bib0012","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.029_bib0013","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.029_bib0014","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.029_bib0015","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Gomez-Bougie","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.029_bib0016","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","author":"Touzeau","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.029_bib0017","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1182\/blood.V128.22.5613.5613","article-title":"A favorable BCL-2 family expression profile may explain the increased susceptibility of the t(11;14) multiple myeloma subgroup to single agent venetoclax","volume":"128","author":"Wu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.029_bib0018","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2021.07.029_bib0019","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.4049\/jimmunol.168.10.4914","article-title":"Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity","volume":"168","author":"Dredge","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2021.07.029_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2021.07.029_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/842945","article-title":"Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma","volume":"2012","author":"Martiniani","year":"2012","journal-title":"Adv Hematol"},{"key":"10.1016\/j.clml.2021.07.029_bib0022","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.029_bib0023","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.029_bib0024","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.029_bib0025","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.029_bib0026","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/cts.12665","article-title":"Model-informed dosing of venetoclax in healthy subjects: an exposure-response analysis","volume":"12","author":"Dave","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clml.2021.07.029_bib0027","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.07.029_bib0028","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.029_bib0029","unstructured":"POMALYST(Pomalidomide Capsules) [prescribing information]. New York, NY: Bristol Myers Squibb Company; 2020 https:\/\/packageinserts.bms.com\/pi\/pi_pomalyst.pdf accessed on March 4, 2021."},{"key":"10.1016\/j.clml.2021.07.029_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","article-title":"NCCN Guidelines Insights: multiple Myeloma, Version 3.2018","volume":"16","author":"Kumar","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2021.07.029_bib0031","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:39:49Z","timestamp":1761871189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021003128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2152265021003128"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.029","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}